专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2021104540A4 Sustained release liposomal delivery of Hydroxyurea in cancer treatment in vitro. 未知
公开(公告)号：AU2021104540A4
公开(公告)日：2022-05-19
申请号：AU2021104540
申请日：2021-07-25
申请人： AKHTAR MD SEMIMUL , BHATTACHARYA ARIN , CHANDEL SAKET SINGH , CHOUHAN SANDHYA , S M SINDHOOR , TYAGI SACHIN
发明人： CHANDEL SAKET SINGH , BHATTACHARYA ARIN , TYAGI SACHIN , CHOUHAN SANDHYA , S M SINDHOOR , AKHTAR MD SEMIMUL
IPC分类号： A61K31/17 , A61K9/127 , A61P35/00
摘要： Abstract: Due to these obstacles, controlled and targeting or localized release technology has been replacing the systemic administration and has shown lots of potential for cancer treatment. Liposomes can be used to provide a sustained release of drugs, which require a prolonged plasma concentration at therapeutic levels to achieve the optimum therapeutic efficacy. In the present work, we formulate liposome containing the anticancer drug 'Hydroxyurea' for sustained delivery. the drug incorporation was carried out using ether injection method. The formulations prepared by ether injection method were evaluated for pH, drug entrapment, in-vitro drug release, drug release kinetics study, pyrogen testing, sterility testing, stability testing. The cumulative drug release for the formulations, prepared by ether injection method, Fl, F2, F3, was found to be 85.37%, 70.83% and 70.22% respectively. The formulations Fl, F2 and F3 showed maximum drug entrapment with values of 74.74%, 65.37% and 61.21% respectively. The drug release kinetics studies suggest that in the formulations prepared by ether injection method, the best fit model was first order for formulation F 1, while for formulations F2 & F3 the best fit model was Korsmayer and for formulation. 'n' exponent value for Pappas model, for formulations Fl, F2 and F3 is greater than 0.89 indicating that formulation is released by super case 2 transport mechanism. All the formulations had suitable pH for use and were found to be stable and giving sustained drug release of the drug over a period of 8 hours. All the formulations showed maximum stability at room temperature and ambient humidity conditions. All these findings show the liposome is a safe, effective, homogeneous, injectable and stable formulation for delivery of Hydroxyurea for Anticancer drugs.

2. 发明专利

AU2021104533A4 SEMISYNTHETIC DERIVATIVES OF NATURAL ORIGIN AS A POTENTIAL ANTIPSYCHOTIC AGENT. 未知
公开(公告)号：AU2021104533A4
公开(公告)日：2022-04-28
申请号：AU2021104533
申请日：2021-08-06
申请人： SAXENA GAURAV , SINGH PARUL , SRIVASTAVA ASHISH , TALREJA SHREYA , TIWARI SHASHANK , TYAGI SACHIN
发明人： TYAGI SACHIN , SRIVASTAVA ASHISH , SINGH PARUL , SAXENA GAURAV , TIWARI SHASHANK , TALREJA SHREYA
IPC分类号： C07J63/00 , A61K31/56 , A61K36/185 , A61P25/18 , C07B31/00 , C07B41/06 , C07B43/04 , G01N30/02 , G01N30/90
摘要： Abstract Natural products have traditionally played an important role in drug discovery and are the foundation for most early-stage drugs. However, despite the promise of these alternative drug discovery methods, there is still a shortage of lead compounds entering clinical trials. Plants have been used to treat HIV, tuberculosis, antibiotics, and all other diseases. Therefore, this study aims to evaluate the potential of lupeol and its semi-synthetic derivatives as an antipsychotic to obtain a new potent antipsychotic. Lupeol is , isolated from the bark of crateava nurvala lupeol. The antipsychotic activity of lupeol derivatives is determined here in this invention. Therefore, the current study aims to evaluate the antipsychotic potential of lupeol and its semi-synthetic derivatives. The stem bark of C. nurvala was cold soaked in 95% ethanol to extract , and concentrated under reduced pressure at 40°C by a vacuum rotary evaporator. The concentrated ethanol extract was defatted with petroleum ether, and was fractionated with chloroform in turn. Lupeol derivatives are prepared by a reaction of in three steps with different amines, aliphatic and aromatic moieties. The antipsychotic activity of a series of lupeol derivatives was measured on a photometer and compulsive behavior (stereotype) was measured in a Plus Maze model of rats. Compared to the basic molecule lupeol, some derivatives of lupeol show stronger activity. The results of this study clearly show that the isolated derivatives of C. nurvala and lupeol and synthetic lupeol analogs have significant antipsychotic activity.

3. 发明专利

AU2021104698A4 A NOVEL POLYHERBAL EXTRACT FOR TREATMENT OF ARTHRITIS WITH POTENTIAL IMMUNOMODULATORY ACTIVITY 未知
公开(公告)号：AU2021104698A4
公开(公告)日：2022-05-26
申请号：AU2021104698
申请日：2021-08-09
申请人： BHARDWAJ NISHANT MR , GAUTAM SHIPRA MS , KHANDIGE PRASANNA SHAMA DR , SINGH SHASHI PRATAP MR , TYAGI SACHIN DR , VATSA ESHA MS
发明人： KHANDIGE PRASANNA SHAMA , TYAGI SACHIN , SINGH SHASHI PRATAP , GAUTAM SHIPRA , VATSA ESHA , BHARDWAJ NISHANT
IPC分类号： A61K36/185 , A61P19/02
摘要： In the present invention we evaluated the immunomodulatory activity of hydroalcoholic and methanolic extract of Combretum indicum and Combretum latialatumin wistar rats. The hydroalcoholic and methanolic polyherbal extracts were given orally at dosage of 100 mg/kg and 200 mg/kg. Levamisol 50 mg/kg used as standard. The carbon clearance test, Cyclophosphamide-induced myelosuppression, Total Leukocyte Count (TLC), and Differential Leukocyte Count (DLC) were used to investigate immunomodulatory action on specific and non-specific immunity (DLC). Hence, present investigation established some pharmacological evidences to support the use of mentioned polyherbal extract as anti-inflammatory agent and immunomodulatoryactivity.

4. 发明专利

AU2021105075A4 A Novel Herbal Formulation for the Prevention and Management of Atherosclerosis 未知
公开(公告)号：AU2021105075A4
公开(公告)日：2022-05-05
申请号：AU2021105075
申请日：2021-08-06
申请人： TYAGI SACHIN , TABISH MOHAMMAD , BABU MOHAMMED BHILAL , KHAN K AMER ALI , AISHA ARAFEEN , AGHA VIQAR
发明人： TYAGI SACHIN , TABISH MOHAMMAD , BABU MOHAMMED BHILAL , KHAN K AMER ALI , AISHA ARAFEEN , AGHA VIQAR
IPC分类号： A61K36/185 , A61K9/00 , A61P9/10
摘要： Abstract Our present invention showed that administration of hydroalcoholic extract of 200 and 400 mg/kg of Phyllanthus niruri was effective to manage hyperlipidemia and platelet aggregation. The active ingredients present here may recover the disorders in lipid metabolism noted in hyperlipidemic state. The present results show that the extracts of Phyllanthus niruri produce a significant reduction in harmful lipids and raised the HDL level which is good cholesterol and thus it act as antihyperlipidemic drug. Similarly, it also inhibits the elevated platelet count. And we also claim that Phyllanthus niruri had lesser side effect than standard drug.

5. 发明专利

DE202022100985U1 Tragbare Impfstoffaufbewahrungsvorrichtung 未知
公开(公告)号：DE202022100985U1
公开(公告)日：2022-03-01
申请号：DE202022100985
申请日：2022-02-22
申请人： CHAKOLKAR MADHAV DEVENDRA , KHANDAI MADHUSMRUTI , KUMAR VERMA NAVNEET , SINGH AMRITA , TYAGI SACHIN , UPADHYAY SWARNAKSHI , VERMA GARIMA , WADHWA SIMRAN , WAL PRANAY
IPC分类号： F25B21/02 , B65D81/18 , F25D3/06 , F25D19/00
摘要： Ein tragbares Aufbewahrungsgerät zum Transport von Medikamenten, die gekühlt aufbewahrt werden müssen, dadurch gekennzeichnet, dass das Gerät umfasst:ein Behälter oder Lager für das Medikament, dass eine kontrollierte Temperatur erfordert, umgeben von Isoliermaterial oder einem verzinkten dünnen Stahlblech;ein Peltier-Modul, dass entweder zum Heizen oder zum Kühlen des Speichers dient;ein Kühlkörper, der als Wärmetauscher fungiert, um die von einem elektronischen oder mechanischen Gerät erzeugte Wärme auf ein flüssiges Medium zu übertragen;ein Kühlgebläse, dass die Temperatur hält und reguliert; undeine Energiequelle zum Zuführen von Energie zu dem System,wobei die tragbare Vorrichtung verwendet wird, um das Fach innerhalb eines Temperaturbereichs zu halten, was entweder durch Kühlen oder Erhitzen des Fachs erfolgen kann.

6. 发明专利

AU2021107097A4 EARLY WARNING SYSTEM FOR DETECTION OF COVID-19 SYMPTOMS IN SENIOR CITIZENS BASED ON AN ARTIFICIAL INTELLIGENCE, IOT AND MACHINE LEARNING 未知
公开(公告)号：AU2021107097A4
公开(公告)日：2021-12-02
申请号：AU2021107097
申请日：2021-08-25
申请人： MEHBODNIYA ABOLFAZL , L SATHISH , SINGHOLI AJAY , NAYAK NIHAR , VAGHELA KRUNAL , LUNAGARIA MUNINDRA , CHAUDHARY SONIA , TYAGI SACHIN , POLKOWSKI ENG , ELNGAR AHMED
发明人： MEHBODNIYA ABOLFAZL , L SATHISH , SINGHOLI AJAY , NAYAK NIHAR , VAGHELA KRUNAL , LUNAGARIA MUNINDRA , CHAUDHARY SONIA , TYAGI SACHIN , POLKOWSKI ENG , ELNGAR AHMED
IPC分类号： G08B21/02
摘要： EARLY WARNING SYSTEM FOR DETECTION OF COVID-19 SYMPTOMS IN SENIOR CITIZENS BASED ON AN ARTIFICIAL INTELLIGENCE, IOT AND MACHINE LEARNING The proposed invention detects and analyzes the corona in the senior citizens. In the proposed system, health sensors are enabled with machine learning, AI for collecting body temperature, heartbeat, respiratory rate, resting pulse oxygen saturation, the partial pressure of oxygen and multiple pulmonary lobes from various body parts of the patients.

7. 发明专利

DE202022101775U1 Ein auf IoT und maschinellem Lernen basierendes Gerät zur Vorhersage und Frühwarnung für Patienten mit psychischen Störungen 未知
公开(公告)号：DE202022101775U1
公开(公告)日：2022-05-27
申请号：DE202022101775
申请日：2022-04-01
申请人： BUTTAR AHMED MATEEN , GANGADHARAN SYAM MACHINATHU PARAMBIL , KHAN IHTIRAM RAZA , SHARMA JEETU , THAREWAL SUMEGH SHRIKANT , TYAGI SACHIN
IPC分类号： G16H50/30
摘要： Ein auf IoT und maschinellem Lernen basierendes Gerät zur Vorhersage und Frühwarnung für Patienten mit psychischen Störungen, gekennzeichnet durchein zentrales Serversystem, umfassend einen digitalen Anzeigemechanismus und ein Tonsystem, welche konfiguriert sind, um Bilder, Videos oder Geräusche anzuzeigen, die den Patienten repräsentieren, die an verschiedene Sensorsysteme angeschlossen sind, um Daten zu erhalten;wobei das zentralisierte Serversystem von einer verantwortlichen Person verwaltet wird, die mit einem authentifizierten Login versehen wurde, um die Daten, die den Patienten repräsentieren, hochzuladen und zu aktualisieren;

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式